Skip to main content

MRNA

Stock
Health Care
Biotechnology

Performance overview

MRNA Price
Price Chart

Forward-looking statistics

Beta
0.83
Risk
70.47%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees5K
Market cap$57.9B

Fundamentals

Enterprise value$5.4B
Revenue$3.2B
Revenue per employee—
Profit margin-105.67%
Debt to equity7.40

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$8.73
Dividend per share—
Revenue per share$8.25
Avg trading volume (30 day)$298M
Avg trading volume (10 day)$281M
Put-call ratio—

Macro factor sensitivity

Growth-1.9
Credit+2.2
Liquidity+0.9
Inflation-4.2
Commodities+1.1
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-3.50
Price to sales3.71
P/E Ratio-3.50
Enterprise Value to Revenue1.71
Price to book1.17

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Here's Why Moderna (MRNA) Fell More Than Broader Market

In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.

Zacks Investment Research (July 18, 2025)
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.

Zacks Investment Research (July 11, 2025)
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.'s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company's COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga (July 10, 2025)
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.

CNBC (June 30, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free